Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Authors: Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V. Marshall, Catherine Vézina, Alberto S. Pappo, Theodore W. Laetsch, Antônio Sérgio Petrilli, Martin Ebinger, Jacek Toporski, Julia Glade Bender, Wayne Nicholls, Elizabeth Fox, Steven G. DuBois, Margaret E. Macy, Susan L. Cohn, Kumudu Pathiraja, Scott J. Diede, Scot Ebbinghaus, Navin Pinto - The Lancet 2019 cited by 343